Piper Sandler Maintains Overweight on ALX Oncology Holdings, Raises Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Christopher Raymond has maintained an Overweight rating on ALX Oncology Holdings (NASDAQ:ALXO) and raised the price target from $8 to $11.
October 11, 2023 | 3:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has maintained an Overweight rating on ALX Oncology Holdings and raised the price target from $8 to $11.
The Overweight rating maintained by Piper Sandler indicates a positive outlook for ALX Oncology Holdings. The increase in price target from $8 to $11 suggests that the analyst believes the stock has potential for significant growth in the short term. This could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100